Oxyphenbutazone is a phenylbutazone derivative, with anti-inflammatory effect. Oxyphenbutazone is a non-selective COX inhibitor. Oxyphenbutazone selectively kills non-replicating Mycobaterium tuberculosis^[1][2]. IC50 & Target: COX^[1] In Vitro: Oxyphenbutazone enhances the anticancer efficiency of methotrexate (MTX) in Hep3B cells^[1].
Oxyphenbutazone (2.5 -7.5 µM; 48 hours) co-treatment with (MTX, 0.25-1.0 µM) shows potential cytotoxicity against Hep3B cells^[1].
Oxyphenbutazone exhibits reparative effects in the hepatocytes^[1].
In Vivo: Oxyphenbutazone (70 mg/kg/week; p.o.; in two divided doses; for 13 weeks) exerts potential anticancer activity when co-treatment with MTX (5.0 or 2.5 mg/kg/week; i.p.)^[1].